Research on Parkinson's disease and its treatment. Covers mitochondrial protection, genetic progression markers, antibody therapies, and disease costs.
A $26 million research project employs advanced technology to understand and treat psychiatric disorders by analyzing brain networks. The project aims to develop neural stimulation therapies to 'unlearn' detrimental signaling patterns, potentially eliminating symptoms.
Researchers have discovered a new treatment that targets the versatile Sigma-1 receptor, improving motor function and reducing inflammation in mice with Parkinson's-like conditions. The results suggest that early activation of this protein could protect brain cells against dopamine loss and associated neural damage.
Researchers at the University of York have developed a sensitive test to detect neurological changes before degeneration occurs. The technique, which uses fruit flies, has shown promise in reducing visual signals and preventing abnormal changes.
Researchers investigated the Pael-R gene's involvement in rotenone-induced Parkinson's disease model cells using RNA interference. The study found that Pael-R expression decreased after treatment, but apoptosis and survival rates did not differ significantly between groups.
Researchers found that Compound Formula Rehmannia modulates neurotransmitter signaling to alleviate levodopa-induced dyskinesia in Parkinson's patients. This traditional Chinese medicine compound showed promise as a potential treatment for the debilitating condition.
Researchers have identified a new and accurate test for Parkinson's disease using 3T MRI scanning technology, known as the 'swallow tail' appearance of the healthy nigrosome. This sign is absent in Parkinson's disease, making it a potential diagnostic tool for clinicians.
Studies by Penn neurologists investigate the potential of statin use and estrogen to delay Parkinson's onset, with promising findings. Telemedicine is also shown to improve access to specialty care for patients with Parkinson's disease.
Oligomers are identified as the enemy that kills nerve cells and causes symptoms of Parkinson's disease. The study reveals two types of oligomers with different degrees of flexibility, which can link up to inhibit fibril formation.
Researchers at Plymouth University will use drug and gene therapies to test whether altering mitochondrial fission or fusion improves dopamine-producing nerve cells in experimental models of Parkinson's Disease. The goal is to identify a potential new therapeutic strategy for this brain disorder, potentially slowing disease progress an...
Researchers at Michigan State University have developed a promising new treatment for Parkinson's disease using a molecular tweezer that prevents protein aggregation. The molecule, CLR01, speeds up protein reconfiguration and has shown success in slowing the first step of aggregation, paving the way for clinical trials.
A study published in Psychiatry Research found that dopamine replacement therapy commonly used to treat motor symptoms of Parkinson's disease was associated with a decline in cognitive performance among depressed Parkinson patients. Mood in depressed Parkinson's patients was also worse while on dopaminergic medications.
Researchers propose that Parkinson's disease could be linked to the immune system attacking healthy neurons, potentially leading to new treatments. The study found that certain neurons display antigens, which are recognized by T-cells and can kill them, raising hopes for a new understanding of the disease.
Researchers at Griffith University's Eskitis Institute have developed a new technique for discovering natural compounds with therapeutic potential. The new screening process involves nuclear magnetic resonance (NMR) spectroscopy and has identified a potential lead in the fight against Parkinson's disease.
A study published in Cell identifies a biological process that triggers a particular form of Parkinson's disease, leading to degeneration of dopamine-producing nerve cells. The research, led by Johns Hopkins Medicine, has shed light on the origins of Parkinson's disease and may lead to new treatments.
A study funded by the National Institutes of Health's National Institute of Neurological Disorders and Stroke found that mutations in the LRRK2 gene may cause excessive protein production, leading to cell death. This could provide a new target for monitoring Parkinson's disease and developing therapies.
Researchers at Newcastle University are investigating Google Glass as an assistive aid to help people with Parkinson's retain their independence. The technology is voice-operated and linked to the internet, providing discreet prompts to support key behaviours typical of Parkinson's.
A $16 million phase III study of isradipine as a potential neuroprotective agent in Parkinson's disease will be conducted at 56 sites in North America. Researchers aim to delay disease progression by protecting dopamine-producing neurons from toxicity.
Researchers analyze baker's yeast to uncover key features in cellular development linked to diseases such as Parkinson's and cancer. The study reveals a precise cellular role for DJ-1 family proteins, which may provide new insight into mechanisms contributing to these conditions.
Researchers at the University of Dundee have identified a critical chemical messenger that protects brain cells against Parkinson's disease. The discovery of phospho-ubiquitin suggests it may be possible to develop drugs to switch on Parkin enzyme by mimicking this molecule, offering new avenues for treatment.
Researchers uncover molecular mechanism behind Parkinson's disease, linking faulty energy production to the Pink1 gene. Correcting this defect may hold promise for treating the condition.
Parkinson's patients without dementia show impaired ability to learn new information, but not recall or recognition of previously learned material. This study suggests that improving new learning is crucial for cognitive rehabilitation interventions.
A recent study published in Neural Regeneration Research reveals that alpha-synuclein can have neuroprotective effects on dopaminergic neurons at very low concentrations. The findings suggest that extracellular alpha-synuclein may enhance neuronal survival via the Akt pathway, challenging previous views of its role in Parkinson's disease.
Researchers found that higher cerebrospinal fluid alpha-synuclein levels predict faster cognitive loss in Parkinson's disease, but not motor symptoms. The study, published in the American Journal of Pathology, offers new insights into PD pathology and potential management strategies.
Researchers at the University of Montreal have identified potential markers for dementia in Parkinson's disease patients with mild cognitive impairments. These markers include thinning in certain cortical areas and subcortical atrophy in grey matter, which may serve as a warning sign for developing dementia.
Researchers used ultra-high-field MRI to identify abnormalities in the substantia nigra, a key region affected by Parkinson's disease. The study showed promising results for early detection and classification of the condition, with high sensitivity and specificity rates.
Researchers are exploring the potential of RM-131, a ghrelin agonist, to treat constipation in Parkinson's patients. The study aims to improve bowel function and reduce symptoms such as abdominal pain and diarrhea.
Researchers at Université Laval discovered unusually high levels of the protein LINGO1 in people with essential tremor, which could lead to an effective treatment. The study found that inhibiting this protein may be a promising treatment avenue for essential tremor.
Researchers at NUS created a highly sensitive fluorescence probe to detect Monoamine Oxidase B (MAO-B) activity, which is elevated in patients with Parkinson's disease. The probe can monitor the progression of the disease and has potential as a biomarker.
A new study will explore the connection between dopamine, a 'feel-good' brain chemical, and hearing loss. The research aims to develop better therapies for people with communication disorders, including those with Parkinson's disease. The $1.6 million grant will fund a team led by Christine Portfors at Washington State University.
Researchers have developed a novel compound that protects mice against developing movement problems associated with Parkinson's disease. The compound, known as '12g', effectively prevented motor deficits linked to PD and showed promise as a potential new therapy.
Researchers aim to create personalized models for individual patients using their clinical data, enabling prediction of disease progress. The goal is to tailor treatment and improve healthcare outcomes for Parkinson's sufferers.
Researchers found that pesticides inhibiting aldehyde dehydrogenase enzyme increase Parkinson's disease risk, especially in people with ALDH2 gene variant. Exposure to multiple pesticides at work and home also increases risk.
A new study by UCLA researchers found that certain pesticides inhibit an enzyme called ALDH, which converts toxic aldehydes into less harmful agents, increasing the risk of Parkinson's disease. The study identified 11 pesticides that increase the risk, particularly in individuals with a common genetic variant of the ALDH2 gene.
Researchers at Max Planck Institute found that GDNF promotes the survival of mitochondria, preventing degeneration associated with a Parkinson's-related gene defect. This discovery could lead to more refined GDNF therapies for patients.
A new study suggests that a population of support cells called astrocytes could provide a promising approach to treat Parkinson's disease. Astrocytes, which are critical to maintaining a healthy environment in the brain, were found to repair multiple types of neurological damage caused by the disease.
Researchers at Duke University found that long-term spinal cord stimulation improved symptoms of Parkinson's-like disease in rats, protecting critical neurons and promoting better survival. The treatment may offer a new option for managing the condition.
A contest for the best particle tracking technique found that each method has its own strengths, but none were deemed unequivocally superior. The challenge, which aimed to track hundreds of intracellular organelles, was marked by oversimplification in image series, limiting algorithm performance on real data.
Researchers found that PINK1 and parkin are key to removing damaged mitochondria through a vesicular trafficking pathway. This early response helps protect against Parkinson's disease, which is linked to mitochondrial dysfunction. The study reveals a distinct quality control mechanism for mitochondria.
ProSavin, a novel gene therapy, has shown promise in reducing motor symptoms of Parkinson's disease by delivering dopamine-making genes directly into the brain. Significant improvements in motor scores were seen in all patients after treatment.
Researchers at the Gladstone Institutes found that mutant LRRK2 accumulation leads to cell death in Parkinson's neurons, and that alpha-synuclein plays a crucial role in this process. By understanding the interplay between these two proteins, scientists may develop new therapeutic strategies to target the disease's underlying mechanisms.
A study published in Neurology found disparities in the utilization of deep brain stimulation (DBS) treatment among Parkinson's patients, with those from lower socioeconomic backgrounds and minority-serving physicians facing significant barriers. DBS out-of-pocket costs are a contributing factor to these disparities.
A Phase 2 trial found that inosine treatment successfully raised participants' urate levels without serious side effects. The study suggests that urate elevation may slow Parkinson disease progression and supports further investigation into its potential as a disease-modifying strategy.
A study published in JAMA Neurology found that inosine treatment increases blood and cerebrospinal fluid urate levels in early Parkinson disease patients, suggesting a potential strategy to slow disability progression. The treatment was also shown to be safe and tolerable, with minimal serious adverse events.
Patients with Parkinson's disease struggle to recognize emotions in facial expressions and speech prosody. After surgery for deep brain stimulation, they show difficulty recognizing disgust and sadness, but this impairment is only temporary.
The Parkin enzyme activates a signal pathway that protects neurons from damage, increasing the expression of protective factors. This process may provide novel therapeutic targets to halt or delay neurodegeneration in Parkinson's disease.
The study involved 23 people with deep brain stimulators and 21 without stimulators, who completed driving tests in a simulator. Those with stimulators performed better on driving tests, especially when the device was turned on.
Scientists have identified a biological pathway linking Gaucher disease and Parkinson's disease. The connection is attributed to the accumulation of defective proteins, leading to an overload of cellular machines that dispose of defective proteins. This cascade triggers cell death in dopamine-producing cells, resulting in PD symptoms.
A new study shows that telemedicine consultations can effectively manage Parkinson's symptoms and improve quality of life. Virtual house calls enable individuals with the condition to live independently while receiving specialized care.
Researchers explore the connection between pesticides and Parkinson's disease, discovering two genetic mutations linked to increased risk in pesticide-exposed individuals. The study highlights the complexity of the disease and the need for further investigation into pesticide exposure and its potential effects on human health.
A review of subthalamic nucleus deep brain stimulation effects on Parkinson's disease patients reveals that while it improves motor features, social maladjustment and certain aspects of quality of life can be negatively impacted. Effective strategies are needed to mitigate these adverse effects and improve patients' overall well-being.
Researchers used RNA interference to identify dozens of genes that may regulate mitochondrial disposal, opening new drug targets for Parkinson's and related disorders. Four helper genes were found to enhance or inhibit tagging of damaged mitochondria.
Scientists at UCLA and Emory University have identified a biochemical signal in the blood associated with the faster-progressing form of Parkinson's. The researchers discovered that N8-acetyl spermidine is significantly elevated in rapid progressors, suggesting its potential as an early biomarker for the disease.
Researchers found that a volatile organic compound emitted by fungi, 1-octen-3-ol, attacks genes responsible for dopamine transport and packaging, leading to Parkinson's-like symptoms in fruit flies. The study suggests a potential link between fungal exposure and the degeneration of dopamine-producing neurons.
Researchers developed a simple dot test called the Triplets Learning Task (TLT) to assess dopamine loss in Parkinson's disease. The test shows promise as a non-invasive way to evaluate dopamine deficiency and may lead to new ways to improve treatment for PD patients.
A study published in Neural Regeneration Research found that Parkinson's patients with psychosis had greater white-matter fiber injury than those without psychosis. This difference may explain why psychosis often occurs in Parkinson's disease patients.
A new algorithm developed at Northwestern University can accurately track physical activity no matter where a patient carries their phone. The study's findings are crucial for improving the health of patients with Parkinson's disease, who may carry their phones in different locations throughout the day.
A study using voxel-based magnetic resonance morphometry found significant gray matter volume loss in Parkinson's disease patients compared to healthy controls. This loss was particularly pronounced in temporal, occipital, parietal, frontal, insular, and cerebellar regions.
A new drug, pimavanserin, has shown significant improvement in reducing psychotic symptoms in Parkinson's disease patients. The study found a 37% improvement in psychotic symptoms compared to placebo, with no worsening of motor symptoms reported.
A study led by TGen found that reduced SMG1 expression may contribute to alpha-synuclein pathology in Parkinson's disease and dementia. The researchers identified SMG1 as a regulator of alpha-synuclein aggregation, suggesting potential new therapeutic targets for treatment.
Researchers have identified a novel Parkinson's disease drug target and a compound capable of repairing neurons derived from human stem cells. Using a discovery platform combining yeast cells with human stem cells, scientists found that the compound reversed alpha-synuclein toxicity in yeast cells and partially rescued neurons in anima...